Recruiting
Phase 3

Ferric Bepectate vs. Ferric Carboxymaltose

Sponsor:

AFT Pharmaceuticals, Ltd.

Code:

NCT07687784

Conditions

Iron Deficiency Anemia (IDA)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ferric Bepectate IV Injection

Ferric Carboxymaltose Injection [Ferinject]

Ferric Carboxymaltose Injection [Injectafer®]

Study Details

Brief summary:

The goal of this clinical trial is to see if a new intravenous iron formulation (Ferric Bepectate IV Injection) can treat adult patients with iron deficiency anemia (IDA) by increasing blood hemoglobin (Hb) as an established formulation (Ferric carboxymaltose). It will also learn about the safety of Ferric Bepectate IV Injection. The main questions it aims to answer are:

  • Does hemoglobin increase by the same amount 6 weeks after each treatment?
  • What medical problems do participants have when being treated with the drug? Researchers will compare single dose treatment plans of Ferric Bepectate to double dose treatment plans of both Ferric Bepectate and Ferric carboxymaltose.

Participants and researchers will know which drug they are being provided (open-label). Participants will visit the clinic 5 times over 6 weeks for checkups, blood tests and questionaries. The first two visits will be seven days apart and include the two doses of iron treatment.

Conditions

Iron Deficiency Anemia (IDA)

Study ID

NCT07687784

Start date

Nov, 2026

Status verified date

Aug, 2026

Completion date

Jul, 2028

Anticipated

Primary completion date

Jun, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Male or female patient at least 18 years old at the time of screening
2. Patients with general iron deficiency anaemia IDA
3. Patients with serum ferritin levels ≤40 ng/mL inclusive
4. Patients with haemoglobin (Hb) levels <10 g/dL
5. Patients ≥ 35 kg body weight
6. The patient has adequate hepatic and renal function defined as a serum aspartate aminotransferase or alanine aminotransferase level that are no more than 3 times the upper limit of the normal range, a serum bilirubin level that is no more than 2 times the upper limit of the normal range and a serum creatinine level of less than 2 mg/dL.
7. The patient is able to understand the protocol and provides informed consent to participate in the study

Exclusion Criteria:

1. Pregnant or breastfeeding patients
2. Female patients not willing to use a safe method of contraception (PEARL index <1) for the full study (screening - V5).
3. Severe physical inability, e.g., ASA physical status IV or V.
4. Non-iron deficiency anaemia, e.g., known Vitamin B12 or folate deficiency, hemoglobinopathy, or unexplained anaemia.
5. Patients with life-threatening anaemia, defined as Hb < 6.5 g/dL.
6. Patient is expected to require a blood transfusion within the study period or has had a blood transfusion within the 30 days prior screening.
7. Anticipated medical need for erythropoiesis-stimulating agents during the study period (screening - V5).
8. Patients with hemodynamic instability due to any ongoing bleeding. Absence of ongoing bleeding will be confirmed either by decision of two independent physicians or by removal of drainage whichever occurs earlier in routine care.
9. Patient has undergone a surgical procedure during the 30 days prior to screening, and/or is expected to undergo a surgical procedure during the study period (screening - V5).
10. Patients with any contraindication to the investigational products, e.g.,

1. known sensitivity to iron or an ingredient of the investigational products,
2. significant history of systemic allergic reactions,
3. hemochromatosis, thalassemia or TSAT >50% as indicator of iron overload,
4. acute or chronic intoxication,
5. infection (patient on non-prophylactic antibiotics),
6. chronic liver disease and/or screening ALT or AST above three times the upper limit of the normal range.
7. chronic kidney disease, defined as GFR <30 mL/min.
11. Primary hematologic disease.
12. Drug or alcohol abuse according to WHO definition.
13. Potentially unreliable patients, and those judged by the investigator to be unsuitable for the study.
14. Current or previous participation in another clinical trial during the last 90 days before screening.
15. Exclusion criteria according to SmPC of Ferric Carboxymaltose.
16. The following concomitant treatments prescribed by a physician for non-iron deficiency anaemia (e.g., known vitamin B12 or folate deficiency), hemoglobinopathy, or unexplained anaemia are not allowed during the study and 24 weeks before screening: Erythropoiesis-stimulating agents, vitamin B12, Folic acid or other I.V. or oral iron products.
17. Estimated life expectancy of <6 months or, for cancer patients, an Eastern Cooperative Oncology Group performance status >1

Study Design

Enrollment

1366 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Ferric Bepectate IV Injection single dose (US/Japan)

Single dose experimental treatment arm for USA and Japan. 50 mg iron/mL. Up to 2000 mg per dose.

experimental: Ferric Bepectate IV Injection single dose (RoW)

Single dose experimental treatment arm for rest of world. 50 mg iron/mL. Up to 2000 mg per dose.

experimental: Ferric Bepectate IV Injection two doses (US/Japan)

Two dose experimental treatment arm for USA and Japan. 50 mg iron/mL. Up to 1000 mg per dose.

experimental: Ferric Bepectate IV Injection two doses (RoW)

Two dose experimental treatment arm for rest of world. 50 mg iron/mL. Up to 1000 mg per dose.

active comparator: Injectafer (US/Japan)

Two dose ferric carboxymaltose active comparator treatment for USA and Japan. 50 mg iron/mL. Up to 750 mg per dose.

active comparator: Ferinject (RoW)

Two dose ferric carboxymaltose active comparator treatment for rest of world. 50 mg iron/mL. Up to 1000 mg per dose.

Interventions

Ferric Bepectate IV Injection

Ferric Bepectate IV Injection 50 mg iron/mL

Ferric Carboxymaltose Injection [Ferinject]

Ferric carboxymaltose (Ferinject®) 50 mg iron/mL in two doses 7-9 days apart

Ferric Carboxymaltose Injection [Injectafer®]

Ferric carboxymaltose (Injectafer®) 50 mg iron/mL in two doses 7-9 days apart

Primary outcome measure

  • Change in hemoglobin comparing one dose Ferric bepectate and two dose Injectafer treatment [ Time Frame: 6 weeks ]
  • Change in hemoglobin comparing one dose Ferric bepectate and two dose Ferinject treatment [ Time Frame: 6 weeks ]
  • Incidence of treatment emergent adverse events [ Time Frame: 2 hours post infusion start ]

Central Contacts and Locations

Central contacts

Locations

Trialmed Phoenix

Recruiting

Phoenix, Arizona, United States, 85020

Contacts

Fiona Marquez

877-469-4154

Principal Investigator:

Shawn Searle

PharmaSouth Research

Recruiting

Coral Gables, Florida, United States, 33146

Contacts

Principal Investigator:

Francisco Quintana, MD

M3 Wake Research - Lake City

Recruiting

Lake City, Florida, United States, 32055

Contacts

Principal Investigator:

Guy Strauss

Trialmed Melbourne

Recruiting

Melbourne, Florida, United States, 32934

Contacts

Principal Investigator:

Murray A Kimmel, MD

Trialmed The Villages

Recruiting

The Villages, Florida, United States, 32162

Contacts

Stephanie Smith

352-361-0901

Principal Investigator:

Angela Okolie, MD

Trialmed Evansville

Recruiting

Evansville, Indiana, United States, 47714

Contacts

Principal Investigator:

Mohammed Allaw

Ingham Nephrology & Hypertension, P.C.

Recruiting

Lansing, Michigan, United States, 48911

Contacts

Principal Investigator:

Brian Cousino

Brookhaven Heart

Recruiting

Patchogue, New York, United States, 11772

Contacts

Principal Investigator:

Saurin Patel

Trialmed Asheboro

Recruiting

Asheboro, North Carolina, United States, 27203

Contacts

Principal Investigator:

Keung Lee

M3 Wake Research - Raleigh

Recruiting

Raleigh, North Carolina, United States, 27612

Contacts

Principal Investigator:

Lisa Cohen

M3 Wake Research - Charleston

Recruiting

Charleston, South Carolina, United States, 29414

Contacts

Principal Investigator:

Donald Hurley

Trialmed Austin

Recruiting

Austin, Texas, United States, 78744

Contacts

Principal Investigator:

Sabrina Merchant

M3 Wake Research

Recruiting

Dallas, Texas, United States, 75246

Contacts

Principal Investigator:

Ralph Cox, MD

PatientCare Clinical Research

Recruiting

Houston, Texas, United States, 77075

Contacts

Principal Investigator:

Anibal Rossel, MD

Trialmed San Antonio

Recruiting

San Antonio, Texas, United States, 78229

Contacts

Principal Investigator:

Tahira Alves, MD

More Information

Sponsor

AFT Pharmaceuticals, Ltd.

Last update posted

Nov 20, 2026

Last verified

Aug, 2026

Keywords

  • Iron infusion
  • Non-inferiority
  • Ferric bepectate
  • Ferric carboxymaltose
  • Ferinject
  • Injectafer

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-21. This information was provided to ClinicalTrials.gov by AFT Pharmaceuticals, Ltd. on 2026-11-20. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.